Heart & blood pressure · Philadelphia area, PA
Heart and blood pressure studies in Philadelphia area, PA
60 recruiting studies have a site in the Philadelphia area. This page includes nearby cities such as Upland, Bryn Mawr, Wynnewood, Abington.
60 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1/Phase 2
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
University of Pennsylvania
- Location
- Philadelphia, PA
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
Cholate Clearance in Fontan and Heart Failure
HepQuant, LLC
- Location
- Philadelphia, PA
- Eligibility basics
- Ages 18+
- Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
- Location
- Bryn Mawr, PA + 64 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure
VisCardia Inc.
- Location
- Philadelphia, PA + 3 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Virtue® SAB in the Treatment of Coronary ISR Trial
Orchestra BioMed, Inc
- Location
- Philadelphia, PA + 21 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Prevail Global Study
Medtronic Vascular
- Location
- Allentown, PA + 53 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
- Location
- Abington, PA + 58 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
- Location
- Lancaster, PA + 40 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated…
Pulnovo Medical, Inc.
- Location
- Mechanicsburg, PA + 12 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
Supira Medical
- Location
- Philadelphia, PA + 24 other US sites
- Eligibility basics
- Ages 18–90
- Recruiting
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
Medtronic Cardiac Ablation Solutions
- Location
- Philadelphia, PA + 20 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
Biotronik, Inc.
- Location
- Paoli, PA + 23 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
NORM-HF Pivotal Study
Foundry Innovation & Research 1, Limited (FIRE1)
- Location
- Philadelphia, PA + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
IRulya Therapeutics Inc.
- Location
- Philadelphia, PA + 1 other US site
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Gossamer Bio USA, Inc.
- Location
- Philadelphia, PA + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
AstraZeneca
- Location
- Abington, PA + 93 other US sites
- Eligibility basics
- Ages 18–130
- RecruitingPhase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Cytokinetics
- Location
- Camp Hill, PA + 80 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
Reprieve Cardiovascular, Inc
- Location
- Philadelphia, PA + 33 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Insmed Incorporated
- Location
- Philadelphia, PA + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Insmed Incorporated
- Location
- Philadelphia, PA + 10 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Tempus AI
- Location
- Philadelphia, PA + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AllRock Bio, Inc.
- Location
- Philadelphia, PA + 10 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Media, PA + 68 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Zenith® Fenestrated+ Clinical Study
Cook Research Incorporated
- Location
- Philadelphia, PA + 29 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.